408 related articles for article (PubMed ID: 29655021)
1. Obesity induced T cell dysfunction and implications for cancer immunotherapy.
Aguilar EG; Murphy WJ
Curr Opin Immunol; 2018 Apr; 51():181-186. PubMed ID: 29655021
[TBL] [Abstract][Full Text] [Related]
2. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
3. Cancer, obesity and immunometabolism - Connecting the dots.
Dyck L; Lynch L
Cancer Lett; 2018 Mar; 417():11-20. PubMed ID: 29253522
[No Abstract] [Full Text] [Related]
4. Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes.
Turbitt WJ; Buchta Rosean C; Weber KS; Norian LA
Immunol Rev; 2020 May; 295(1):203-219. PubMed ID: 32157710
[TBL] [Abstract][Full Text] [Related]
5. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
Zhao Y; Shao Q; Peng G
Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
[TBL] [Abstract][Full Text] [Related]
6. Obesity altered T cell metabolism and the response to infection.
Green WD; Beck MA
Curr Opin Immunol; 2017 Jun; 46():1-7. PubMed ID: 28359913
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Barriers to T Cell Function in Tumors.
Sugiura A; Rathmell JC
J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
[TBL] [Abstract][Full Text] [Related]
8. Immune metabolism in PD-1 blockade-based cancer immunotherapy.
Kumar A; Chamoto K
Int Immunol; 2021 Jan; 33(1):17-26. PubMed ID: 32622347
[TBL] [Abstract][Full Text] [Related]
9. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
10. Dysfunctional T cell metabolism in the tumor microenvironment.
Beckermann KE; Dudzinski SO; Rathmell JC
Cytokine Growth Factor Rev; 2017 Jun; 35():7-14. PubMed ID: 28456467
[TBL] [Abstract][Full Text] [Related]
11. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
Li X; Xu W
Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
[TBL] [Abstract][Full Text] [Related]
12. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.
Crespo J; Sun H; Welling TH; Tian Z; Zou W
Curr Opin Immunol; 2013 Apr; 25(2):214-21. PubMed ID: 23298609
[TBL] [Abstract][Full Text] [Related]
13. Regulatory circuits of T cell function in cancer.
Speiser DE; Ho PC; Verdeil G
Nat Rev Immunol; 2016 Oct; 16(10):599-611. PubMed ID: 27526640
[TBL] [Abstract][Full Text] [Related]
14. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
16. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.
Liu X; Hoft DF; Peng G
J Clin Invest; 2020 Mar; 130(3):1073-1083. PubMed ID: 32118585
[TBL] [Abstract][Full Text] [Related]
17. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
Ho PC; Kaech SM
Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment.
Ma F; Vayalil J; Lee G; Wang Y; Peng G
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34642246
[TBL] [Abstract][Full Text] [Related]
19. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
20. Turning tumors into vaccines: co-opting the innate immune system.
van den Boorn JG; Hartmann G
Immunity; 2013 Jul; 39(1):27-37. PubMed ID: 23890061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
